Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | USP5 | P45974 | 4/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | SNCA | P37840 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.44 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL341580 | 0.86 | PSMB11 (0.53) | CES2CES1EGLN1RAB9A | |
| SCHEMBL12181342 | 0.83 | EGLN1 (0.58) | EGLN1USP5HDAC6RAB9ANPC1 | |
| SCHEMBL17950994 | 0.83 | GCG (0.54) | CES2CES1L3MBTL1RAB9ANPC1 | |
| SCHEMBL15630976 | 0.83 | KDM4E (0.51) | EGLN1RAB9ANPC1HDAC3 | |
| SCHEMBL6651826 | 0.83 | MAPT (0.56) | EGLN1USP5HDAC6RAB9ANPC1 | |
| SCHEMBL23014377 | 0.83 | ALDH1A1 (0.53) | CES2CES1L3MBTL1RAB9ANPC1 | |
| SCHEMBL15610534 | 0.82 | USP5 (0.45) | EGLN1USP5HDAC6RAB9ANPC1 | |
| SCHEMBL2981411 | 0.81 | EGLN1 (0.45) | CES2EGLN1HDAC6RAB9AHDAC3 | |
| SCHEMBL6068233 | 0.81 | CES2 (0.55) | CES2CES1L3MBTL1RAB9ANPC1 | |
| SCHEMBL15630978 | 0.80 | KEAP1 (0.59) | EGLN1RAB9AHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900629-A2 | F-18 RADIOLABELED COMPOUNDS FOR DIAGNOSING AND MONITORING KIDNEY FUNCTION | Kasina Laila Innova Pharmaceuticals Private Ltd. (IN) | 2015-08-05 | — | — | EP | disclosed |
| US-8912341-B2 | Enantioselective N-heterocyclic carbene-catalyzed annulation reactions with imidazolidinones | NORTHWESTERN UNIVERSITY (US) | 2014-12-16 | — | — | US | disclosed |
| US-8906344-B2 | F-18 radiolabeled compounds for diagnosing and monitoring kidney function | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2014-12-09 | — | — | US | disclosed |
| US-20140206886-A1 | Enantioselective N-heterocyclic carbene-catalyzed annulation reactions with imidazolidinones | NORTHWESTERN UNIVERSITY (US) | 2014-07-24 | — | — | US | disclosed |
| WO-2014045306-A2 | F-18 RADIOLABELED COMPOUNDS FOR DIAGNOSING AND MONITORING KIDNEY FUNCTION | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2014-03-27 | — | — | WO | disclosed |
| US-20140086837-A1 | F-18 RADIOLABELED COMPOUNDS FOR DIAGNOSING AND MONITORING KIDNEY FUNCTION | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2014-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206886-A1 | Enantioselective N-heterocyclic carbene-catalyzed annulation reactions with imidazolidinones | NISCH, NIM1K, CDK18 | CES2 1380/4885CES1 1518/4885EGLN1 3178/4885 |
| US-20140086837-A1 | F-18 RADIOLABELED COMPOUNDS FOR DIAGNOSING AND MONITORING KIDNEY FUNCTION | SLCO1B1, SLCO1B3, SLCO2B1 | CES2 1898/4885CES1 956/4885EGLN1 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.